Novartis offers to buy rest of Chiron
Article Abstract:
Novartis AG of Switzerland has offered to acquire Chiron Corp. of the United States for $4.5 billion. The Swiss pharmaceutical giant already owns 42 percent of the beleaguered United States biotechnology company and has offered to acquire the rest of the company for $40 per share.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Novartis agrees to acquire the rest of Chiron for $5.1 billion
Article Abstract:
Novartis AG of Switzerland is to acquire the remaining stake in Chiron Corp. of the United States for $5.1 billion. The pharmaceutical giant already owned 42 percent of the biotechnology company and is planning to turn around the vaccine business.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Biotech industry heads toward IPO boomlet
Article Abstract:
Several biotechnology firms are planning to hold initial public offerings (IPOs), after being previously skeptical about the IPO market. However, analysts are raising concerns about the quality of the planned IPOs.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Vivendi would sell assets to save Bertelsmann deal. Vivendi agrees to buy BMG for $2.1 billion, besting rivals
- Abstracts: Banks cut ties to North Korea. North Korea agrees to give up nuclear arms
- Abstracts: British Petroleum to acquire Amoco in $48.2 billion deal. U.N council nears Iraq resolution
- Abstracts: Volkswagen aims to triple U.S. sales. Volkswagen sees additional gains in profit, revenue. VW launches redesigned Golf